Challenges in Patient Accessibility to Regenerative Medicines: A Comprehensive Review

By Tingting Qiu, Mondher Toumi

A comprehensive review of the challenges that exist in patient accessibility to regenerative medicines (RMs), presenting clinical trials, marketing authorization, HTA, pricing, reimbursement, affordability, payment and partnership agreements of RMs and commercialization. Specifically, we investigated how COVID-19 has impacted the RM industry by elaborating on the disruptions it caused but also the new opportunities it brought. The ultimate goal of this work is to make strategic recommendations for manufacturers and decision-makers on effective strategies to address the above obstacles and facilitate patient access to promising regenerative medicines.

What is Regenerative Medicine?

Regenerative medicine (RM) is an emerging interdisciplinary field aiming to replace or regenerate human cells, tissues, or organs in order to restore normal function. RM holds the promise of revolutionizing treatment in the 21st century. RMs bring new hope for some previously untreatable diseases, as well as holding promise for the treatment of common chronic diseases. Rapid advancements in biotechnology and improved understanding of disease pathophysiology have attracted tremendous interests in the development of RMs.

The High Cost of RMs: A Sustainability Challenge

One of the significant challenges in patient accessibility to regenerative medicines is the high cost associated with them. The high cost of RMs may challenge the sustainability of healthcare insurers (public and private). This issue needs to be addressed to ensure that these promising treatments are accessible to all who need them.

Product Details

Publisher: CRC Press; 1st edition (May 23, 2023)
Language: English
Pages: 232
ISBN-10: 1032431989
ISBN-13: 978-1032431987